HTG Molecular Diagnostics Inc (HTGM)

NASDAQ
4.06
+0.04(+0.99%)
  • Volume:
    59,141
  • Bid/Ask:
    4.02/4.44
  • Day's Range:
    4.02 - 4.2691

HTGM Overview

Prev. Close
4.02
Day's Range
4.02 - 4.2691
Revenue
8.55M
Open
4.02
52 wk Range
3.78 - 13.8
EPS
-4.55
Volume
59,141
Market Cap
25.23M
Dividend (Yield)
N/A (N/A)
Average Vol. (3m)
112,530
P/E Ratio
-
Beta
1.34
1-Year Change
-30.2%
Shares Outstanding
6,214,400
Next Earnings Date
May 13, 2021
What is your sentiment on HTG Molecular Diagnostics Inc?
or
Market is currently closed. Voting is open during market hours.

HTG Molecular Diagnostics Inc News

HTG Molecular Diagnostics Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellBuy
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Buy
SummaryStrong SellStrong SellStrong SellStrong SellStrong Buy

HTG Molecular Diagnostics Inc Company Profile

HTG Molecular Diagnostics Inc Company Profile

HTG Molecular Diagnostics, Inc. is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company's HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development. The Company's HTG Edge and HTG EdgeSeq platforms automate the molecular profiling of genes and gene activity using its nuclease protection chemistry on a range of biological samples. The Company's HTG EdgeSeq chemistry, together with its HTG Edge or HTG EdgeSeq instrumentation and software, automates and adapts its nuclease protection chemistry to enable analysis using next generation sequencing (NGS) instrumentation. The HTG EdgeSeq system utilizes substantially the same sample preparation reagents as its original chemistry, but allows for read out on an NGS instrument.

Read More
  • The company has recently announced the feasibility for a planned whole transcriptome panel, now the next phase is the optimization phase, and hopefully the product will be commercialized by the third quarter 2021. I am very optimistic about this stock!
    0
    • ertvery bad investment
      3
      • I will buy it...Sweet profits ahead
        1
        • Good luck. Any reason you are buying this? Or just hedging bets?
          0
        • I was wondering Did you get your sweet profit ? from feb till now? lol
          0
      • I will buy it...Sweet profits ahead
        0
        • buy?
          0
          • See you later.
            0
        Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
        Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.